Nebivolol Ipca Laboratories

Nebivolol, the active ingredient in Nebivolol Ipca Laboratories, is a beta blocker presented as an oral tablet for oral use. It is used to treat hypertension and heart failure in adult patients. GNH USA supplies Nebivolol Ipca Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker indicated for cardiovascular conditions. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of chronic heart failure. - Elderly patients with hypertension: provides effective blood‑pressure control with a favorable tolerability profile.

Nebivolol may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general weakness. - Bradycardia: resting heart rate below normal. - Nasal congestion or rhinorrhoea. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or sinus arrest. - Symptomatic hypotension with fainting. - Bronchospasm in patients with asthma or COPD. - Atrioventricular block or other cardiac conduction disturbances. - Allergic reactions such as rash, pruritus, or angio‑edema. - Elevated liver enzymes indicating hepatic injury.

Before initiating Nebivolol therapy, clinicians should consider several safety measures. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Heart rate assessment: avoid use in patients with baseline severe bradycardia. - Respiratory caution: use carefully in asthma or chronic obstructive pulmonary disease. - Concomitant beta‑blockers: avoid duplicate therapy to prevent additive effects. - Renal/hepatic impairment: dose adjustment may be required in moderate to severe dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic and inotropic effects. - Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): risk of severe bradycardia and AV block. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase Nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: may enhance hypotensive effect. - Diuretics: monitor electrolytes and blood pressure. - NSAIDs: can attenuate antihypertensive response. - Antidiabetic agents: may mask hypoglycaemia symptoms. - Certain antidepressants (e.g., SSRIs): watch for additive heart‑rate effects.